Abstract
Antiretroviral therapy (ART) has significantly reduced morbidity and increased life expectancy of individuals infected with human immunodeficiency virus (HIV). Consequently, non-acquired immunodeficiency syndrome (AIDS)-defining malignancies are increasing in frequency, which necessitates the concurrent use of antineoplastics and ART. Although drug interactions are a major concern when combining these agents, there is currently limited guidance on dose adjustments required to maintain safe and efficacious drug exposure.
Original language | English (US) |
---|---|
Pages (from-to) | 370-372 |
Number of pages | 3 |
Journal | Clinical pharmacology and therapeutics |
Volume | 95 |
Issue number | 4 |
DOIs | |
State | Published - Apr 2014 |
ASJC Scopus subject areas
- Pharmacology
- Pharmacology (medical)